mProX™ Human STK4 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

STK4, also known as MST1, is a serine/threonine kinase that plays a role in various diseases and conditions. In clear cell renal cell carcinoma (ccRCC), STK4 is found to be a prognostic biomarker and its expression is correlated with immune infiltrates. This suggests that STK4 may be a reliable prognostic predictor and could help identify new strategies for treating ccRCC patients. In a case report of a patient with epidermodysplasia verruciformis-like lesions, STK4 deficiency was identified as an underlying cause of the condition. The study suggests that STK4 deficiency is associated with combined immunodeficiency and skin lesions. Furthermore, STK4 is also found to be involved in the pathogenesis of other diseases such as viral skin infections and multiple myeloma. In viral skin infections, STK4 deficiency is identified in patients with unusual viral skin infections, indicating an inborn error of immunity. In multiple myeloma, STK4 negatively regulates the tumor suppressor protein TAZ and its expression is associated with poor clinical outcomes. Inhibition of STK4 leads to increased TAZ expression and sensitizes myeloma cells to frontline antimyeloma agents. Additionally, ginsenoside Rh2, a natural compound, is found to attenuate the progression of non-small cell lung cancer (NSCLC) by targeting the miR-28-5p/STK4 axis and inactivating Wnt/β-catenin signaling. This study suggests that G-Rh2 could serve as a potential therapeutic agent for NSCLC. Overall, STK4 has implications in various diseases and conditions, including cancer, immune disorders, and viral infections, highlighting its diverse applications in the field of medicine.